8.00 am Registration & Coffee

8:45 am Chair’s Opening Remarks

Improving Patient Outcomes of Next-Generation Bacteriophage Therapy

9:00 am Shedding Light on Success of Bacteriophage Clinical Trials on Humans

  • Urania Rappo Senior Director - Clinical Development, BiomX


  • Demonstrating clinical safety and efficacy of phage therapy in patients with cystic fibrosis
  • Unpicking positive results from clinical data on chronic pulmonary infections to expand pipeline progress
  • Advancing clinical trials to the next steps to optimize final success of combating P. aeruginosa

9:30 am Advancing Phage-Based Therapies Towards Clinical Studies

  • Paul Kim Chief Development Officer, Locus Biosciences


  • Revealing clinical data highlights from unblinded stage of phage-led study
  • Implementing insights to ongoing Phase II trial for blinded study on patients to treat UTIs
  • Targeting population to improve patient recruitment and health outcomes during clinical trials

10:00 am Advanced Phage Profiling to Guide Therapeutic Development & Inform Drug Discovery Pipelines

  • Heidi Hanson Hau Vice President, Scientific Affairs & Partnerships, Clinical-Microbiomics


  • Virome profiling based on the most extensive virus database available to enable detection of more than 64,000 virus species (vOTUs)
  • Superior Accuracy: Demonstrates significant advancements over other pipelines in benchmarking studies and detects a broader range of phage species with nearly zero false positives
  • Phage Behavior Insights: Provides detailed annotations on phage lifestyles and precise host mapping to enhance understanding of phage-bacterial interactions

10:30 am Morning Refreshments & Speed Networking

11:30 am Management of Diabetic Foot Infections Using Phage Products: Unveiling TP-102 Phase IIb Study


  • Articulating regulatory challenges in phage development to enable treatment of human disease 
  • Showcasing design of clinical trial protocol for safe and effective Phase IIb phage product 
  • Highlighting critical findings of phage therapy to treat diabetic foot infections from preliminary results

12:00 pm Armata Clinical Trials Overview of Bacteriophage Administration for Difficult-to-Treat Infections


  • Value of a phage cocktail approach in subjects with chronic pseudomonal respiratory infections
  • Similarities of phage distribution and phage kinetics between cystic fibrosis and non-cystic fibrosis bronchiectasis subjects administered nebulized phage (AP-PA02)
  • Purity of high dose S. aureus phage (AP-SA02) and ability to safely dose escalate intravenously over multiple days in subjects with S. aureus bacteremia

12.30 pm Lunch & Networking

Innovating in Phage Technology & Artificial Intelligence to Enhance Efficacy Profile

1:30 pm Lessons Learned from Google: Applying AI in Practice for Development & Production of Bacteriophage


  • Understanding the variations in machine learning (supervised, unsupervised, self-supervised) for application of AI
  • Unveiling the benefits of implementing AI to provide a clearer direction for therapeutic phage use
  • Selecting optimal data and algorithms to overcome common pitfalls when leveraging AI and bioinformatics

2:00 pm Gaining Insights into Clinical Testing of Engineered Phage Cocktail Targeting E. coli


  • Revealing clinical results from Phase I trial on orally dosed, CRISPR-armed phage designed for precision killing of E. coli
  • Improving safety, tolerability, and microbiological efficacy endpoints for superior patient results
  • Consolidating the next steps in development and success of CRISPR-led phage therapy

2.30 pm Afternoon Refreshments & Poster Session

3:15 pm Discovering, Purifying & Selecting the Appropriate Cocktail Phage for Personalized Medicine


  • Integrating bioinformatics to determine safety and efficacy of phage in humans
  • Creating lab-based solutions for individual phage development and production for higher specificity
  • Establishing phage pipeline to delve into medical, pharmaceutical, and regulatory achievements

Streamlining Manufacturing Processes for Bacteriophage Commercialization

3:45 pm Process Monitoring & Controlling Critical Process Parameters to Obtain Higher Phage Yields in Upstream & Downstream Manufacturing


  • Understanding the use of online sensors for upstream production of phage in stirredtank bioreactors
  • Delving into the modelling and optimization of upstream production of phage products
  • Highlighting downstream processing of phage using tangential flow filtration and chromatography – leveraging MALDI-TOF, MADLS, and other analytical approaches forcharacterizing phage drug substance and linking critical process parameters with critical quality attributes

4:15 pm Chair’s Closing Remarks & End of Conference Day One

4:30 pm Drinks Reception